- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05449678
Low cArbohydraTe dIeT and aUtomated Insulin Delivery System for Type 1 DiabetEs (LATITUDE)
The LATTITUDE Study - Low Carbohydrate Diet and Automated Insulin Delivery System for Type 1 Diabetes
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Problems: Despite significant technological and treatment advances for people living with with type 1 diabetes (PWT1D), time in optimal glycemic targets remains difficult to achieve (between 4.0 and 10.0 mmol/L). On the other hand, there is increasing interest in low-carbohydrate diets in the general population (often for weight control), but also in people with diabetes, to help achieve glycemic control (associated with an increase in time in range (TIR).
Automated insulin delivery (AID) systems, including a continuous glucose monitor (CGM) coupled to an insulin pump with an integrated infusion algorithm, increase TIR by approximately 2 hours per day and reduce time in hypoglycemia by 30 minutes, compared to conventional treatments for type 1 diabetes. However, maintaining an optimal TIR remains a significant challenge for PWT1D, despite the increasing use of this technology.
AID systems in combination with a low-carbohydrate diet to optimize TIR have not been studied.
Objectives: To investigate whether low-carb diets improve glucose management and the feasibility of adopting low-carb diets among PWT1D using an AID.
Methods: This is a 12-month prospective, open-label, randomized, controlled study in adults living with type 1 diabetes, with the first 12 weeks as the main study phase and the rest as the extended study phase.
- Admission period (2-4 weeks): Optimization of insulin doses, validation of carbohydrate calculations and maintenance of usual diet.
- Main study period (3 months): Study assignment diet (low carbohydrate or usual).
- Extensive study phase (9 months): Maintenance of assignment diet (if possible) with less frequent visits (observation period).
Hypothesis: The low-carb diet would increase the TIR% (primary outcome) by a mean of 8% (SD 8) compared with the usual diet. Power calculation: Using mean 8% (SD 8), that 38 adults (19 for each group) would provide 80% power at the 5% significance level to detect differences between the two interventions, after considering a 10% drop-out rate.
Full analysis set is defined as participants who have finished recruitment. Per-protocol set is defined as participants who have finished recruitment and have at least 70% of CGM data, at least 70% time in closed-loop mode and at least 4 full days of diet data during week 3-4. The efficiency analysis will be performed using the per-protocol set. The safety analysis will be performed using the full analysis set.
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Valérie Boudreau, PhD
- Phone Number: 514 987-5643
- Email: valerie.boudreau@ircm.qc.ca
Study Contact Backup
- Name: Zekai Wu, MD, PhD
- Email: zekai.wu@ircm.qc.ca
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Men and women ≥ 18 years old
- Duration of T1D or latent autoimmune diabetes in adults (LADA) ≥ 12 months
- On automated insulin delivery system for ≥ 3 months
- Own a smartphone or tablet to use the mobile application: Keenoa
- Willing to share personal CGM data during the study period
- Reporting daily food intake >3350 kJ (1200 kcal)
- Time in closed-loop mode during run-in period > 70%
Exclusion Criteria:
- Self-reported having a diet with < 35% energy from carb.
- Seldom (<20% of scenario) or never count carbohydrate intake.
- Self-reported clinically significant nephropathy (eGFR < 30 ml/min/1.73m2, planned or on dialysis or already followed by a nephrologist), or retinopathy (e.g., proliferative retinopathy with ongoing active treatment such as laser photocoagulation or planned surgery)
- Recent (< 6 months) acute macrovascular event (e.g., acute coronary syndrome or cardiac surgery).
- Self-reported significant liver disease (e.g. cirrhosis, active hepatitis, liver transplantation)
- Self-reported uncontrolled thyroid disease (unless stable treatment for 8 weeks at inclusion with TSH within target range).
- Self-reported one or more severe hypoglycemic episodes within two weeks of screening.
- Self-reported one or more severe hyperglycemic episodes requiring hospitalization in the last 3 months.
- Anticipated therapeutic change (including change of insulin type [switch to biosimilar is not considered as insulin change] and/or type of CGM sensor, insulin pump or AID between admission and end of the study.
- To limit risk of interference for CGM accuracy: anticipated need to use acetaminophen during the study period at a dose above 1g every 6 hours and current or anticipated use of Hydroxyurea.
- Plan to go abroad in a foreign country during the study period for a duration > 4 weeks.
- Pregnancy (ongoing or current attempt to become pregnant).
- Breastfeeding.
- Using regular insulin (Entuzity U500, Novolin ge Toronto or Humulin R).
- Current use of glucocorticoid medication (except low stable dose and inhaled steroids and stable adrenal insufficiency treatment e.g., Cortef®).
- Current use of agents affecting gastric emptying (Motilium®, Victoza®, Ozempic®, Trulicity®, Byetta® and Symlin®) as well as oral anti-diabetic agents (Metformin, Prandase®, DPP-4 inhibitors) unless at a stable dose for 3 months and without anticipated change during the study.
- Current use of SGLT-2 inhibitors unless at a stable dose for at least 3 months, without anticipated change during the study and appropriate ketone testing is performed.
- Other serious medical illnesses which likely interfere with study participation or with the ability to complete the study by the judgment of the investigator.
- In the opinion of the investigator, a participant who is unable or unwilling to complete the study.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
No Intervention: Control diet
Usual diet (45% of daily energy intake from CHO)
|
|
Experimental: Low carb diet
Low-carb diet (25% of daily energy intake from CHO)
|
A close nutritional follow-up will take place with a qualified nutritionist to adapt the participants' usual diet to their assignment diet.
This is not a strict diet to follow or a ketogenic diet.
Nutritional modifications will be based on the participants' usual diet to improve adherence (personalized follow-up).
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Time in range (TIR)
Time Frame: 12 weeks
|
The comparison between low-carb diet and usual diet regarding percentage of time of glucose levels spent between 3.9 and 10.0 mmol/L (TIR%) based on sensor glucose value during week 11 and 12 (24-hour).
|
12 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Adherence
Time Frame: 1 year
|
Adherence to the prescribed diet (average % CHO intakes/day; number of days with +/- 5% CHO of prescribed diet; % meals following +/-5% targeted CHO)
|
1 year
|
Collaborators and Investigators
Investigators
- Study Director: Remi Rabasa-Lhoret, MD, PhD, IRCM
Study record dates
Study Major Dates
Study Start (Anticipated)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2023-1182
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Type 1 Diabetes
-
Poznan University of Medical SciencesUnknownDiabetes Mellitus Type 1 | Remission of Type 1 Diabetes | Chronic Complications of DiabetesPoland
-
Eledon PharmaceuticalsWithdrawnBrittle Type 1 Diabetes MellitusUnited States
-
National Institute of Allergy and Infectious Diseases...PPD; Rho Federal Systems Division, Inc.; Immune Tolerance Network (ITN)CompletedType 1 Diabetes Mellitus | T1DM | T1D | New-onset Type 1 Diabetes MellitusUnited States, Australia
-
Hoffmann-La RocheCompletedType 2 Diabetes, Type 1 DiabetesAustria, United Kingdom
-
Shanghai Changzheng HospitalRecruitingBrittle Type 1 Diabetes MellitusChina
-
Capillary Biomedical, Inc.TerminatedType 1 Diabetes | Type 1 Diabetes Mellitus | Diabetes Mellitus, Type I | Diabetes Mellitus, Insulin-Dependent, 1 | IDDMAustria
-
Capillary Biomedical, Inc.CompletedDiabetes Mellitus, Type 1 | Type 1 Diabetes | Type 1 Diabetes Mellitus | Diabetes Mellitus, Insulin-Dependent, 1Australia
-
AstraZenecaCompletedType 2 Diabetes Mellitus | Type 1 Diabetes MellitusUnited States
-
NYU Langone HealthNational Heart, Lung, and Blood Institute (NHLBI)Recruiting
-
Rabin Medical CenterDreaMed DiabetesTerminated
Clinical Trials on Low-carb diet
-
Hvidovre University HospitalUniversity of Copenhagen; Danish Research Centre for Magnetic ResonanceCompletedDiabetes | Metabolic Syndrome | NAFLD | Overweight and ObesityDenmark
-
Université de SherbrookeNestlé Health Science SpainActive, not recruitingAlzheimer Disease | Glucose MetabolismCanada
-
Region StockholmRecruitingDiabetes Mellitus Type 2 in ObeseSweden
-
University Hospital, Basel, SwitzerlandRecruitingObesity | Glucose IntoleranceSwitzerland
-
University Psychiatric Clinics BaselNot yet recruitingDepressive Disorder | Major Depressive Disorder | Depression, Bipolar
-
Universidade do PortoNOVA Medical School | Faculdade de Ciências Médicas, Universidade Nova de... and other collaboratorsActive, not recruiting
-
Vanderbilt University Medical CenterRecruitingDiabetes Mellitus, Type 1United States
-
The University of Texas Health Science Center at...CompletedDiabetic Kidney Disease | Weight Loss | Cognitive Function | Type2 Diabetes | Diabetic ControlUnited States
-
University of Sao PauloCompleted
-
University of North Carolina, Chapel HillTakeda Pharmaceuticals North America, Inc.CompletedOverweight | Gastroesophageal Reflux Disease | Acid Reflux DiseaseUnited States